For in vitro diagnostic use. Others Elecsys PlGF IVD Elecsys® PlGF CPS_000498 05 144 671 190 5 144 671 190 05144671190 5144671190 05144671190 PLGF Elecsys cobas e 100 Elecsys PlGF 04015630925391 Reagents, kits 100 tests cobas e 411/601/602 true 05 144 671 161 5 144 671 161 05144671161 5144671161 05144671161 PLGF RUO Elecsys cobas e 100 PlGF RUO 04015630939121 Reagents, kits 100 tests cobas e 411/601/602 true 09 015 434 190 9 015 434 190 09015434190 9015434190 09015434190 PLGF Elecsys E2G 100 V2 Elecsys PlGF 07613336172124 Reagents, kits 100 tests cobas e 402/801 true 07 027 648 190 7 027 648 190 07027648190 7027648190 07027648190 PLGF Elecsys E2G 100 Elecsys PlGF 04015630940479 Reagents, kits 100 tests cobas e 402/801 true 09 015 418 160 9 015 418 160 09015418160 9015418160 09015418160 PLGF Elecsys cobas e 100 V2 Elecsys PlGF 07613336230756 Reagents, kits 100 tests cobas e 411/601/602 true 05144671500 Elecsys PlGF en 12 FF00000004837C0E FF000000004A5E0E 05144671190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of placental growth factor (PlGF) in human serum.The Elecsys PlGF assay is used in combination with the Elecsys sFlt‑1 assay to determine the sFlt‑1/PlGF ratio. The sFlt‑1/PlGF ratio is intended for use as an aid in the diagnosis of preeclampsia in conjunction with other diagnostic and clinical information.In addition the sFlt‑1/PlGF ratio is intended for use as an aid in short-term prediction of preeclampsia (rule-out and rule-in) in pregnant women with suspicion of preeclampsia in conjunction with other diagnostic and clinical information.This assay is intended for the use as one component, in combination with other parameters, to evaluate the risk of early-onset preeclampsia during the first trimester of pregnancy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 09015434501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783E30E FF00000007826D0E 09015434190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027648500 Elecsys PlGF en 6 FF000000050D5B0E FF00000004EB2B0E 07027648190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of placental growth factor (PlGF) in human serum.The Elecsys PlGF assay is used in combination with the Elecsys sFlt‑1 assay to determine the sFlt‑1/PlGF ratio. The sFlt‑1/PlGF ratio is intended for use as an aid in the diagnosis of preeclampsia in conjunction with other diagnostic and clinical information.In addition the sFlt‑1/PlGF ratio is intended for use as an aid in short-term prediction of preeclampsia (rule-out and rule-in) in pregnant women with suspicion of preeclampsia in conjunction with other diagnostic and clinical information.This assay is intended for the use as one component, in combination with other parameters, to evaluate the risk of early-onset preeclampsia during the first trimester of pregnancy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09015418501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783E00E FF00000007825C0E 09015418160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® PlGF

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

Technical Documents

Access important product documentation including relevant certificates and other resources.